Silexion Therapeutics Details Positive SIL204 Data, Announces Phase 2/3 Trial Initiation in Q2 2026
SLXN is trading near its 52-week low of $1.65 (11% above the low) on light trading volume (0.1× avg).
Summary
Silexion Therapeutics released a corporate presentation detailing promising preclinical and first-generation clinical data for its lead asset, SIL204, and announced the initiation of its Phase 2/3 clinical trial in Q2 2026 for locally advanced pancreatic cancer.
Key Events · Product Development and Regulatory · SLXN
-
Phase 2/3 Trial Initiation
SIL204, targeting KRAS mutations, is set to begin its Phase 2/3 clinical trial in Q2 2026 for locally advanced pancreatic cancer.
-
Promising Clinical Data
First-generation siRNA (Loder) showed robust antitumor activity and improved overall survival in Phase 2 for pancreatic cancer.
-
Strong Preclinical Results
Second-generation SIL204 demonstrated broad and potent inhibition across various human KRAS mutations and synergistic anti-tumor activity with chemotherapy.
-
Favorable Toxicology Profile
Extended single-dose GLP toxicity studies confirmed SIL204 was well-tolerated with no systemic toxicity, establishing safety margins for clinical trials.
Analysis · SLXN · Life Sciences
This 8-K provides a comprehensive update on Silexion Therapeutics' lead oncology asset, SIL204, significantly advancing the company's clinical development narrative. The detailed presentation of positive preclinical and first-generation clinical data, coupled with the concrete timeline for initiating a pivotal Phase 2/3 trial in Q2 2026, represents a major de-risking event for this micro-cap biotech. The drug's focus on KRAS mutations in pancreatic cancer addresses a high unmet medical need. Investors should view the progression into late-stage trials, supported by strong safety and efficacy signals, as a critical step towards potential commercialization and a significant positive catalyst for the stock. The established manufacturing collaborations further bolster the feasibility of their development plan.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 37.4% of the 3389 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLXN was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7M. The 52-week trading range was $1.65 to $26.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.